

Autologous Cell Therapy Market By Therapeutic area (Cancer, Others), By End user (Hospitals, Cancer treatment centers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Market Report | 2022-10-01 | 188 pages | Allied Market Research

AVAILABLE LICENSES:

- Cloud Access License \$3456.00
- Business User License \$5730.00
- Enterprise License \$9600.00

Report description:

The global autologous cell therapy market was valued at \$4,307.06 million in 2021, and is projected to reach \$29,049.87 million by 2031, registering a CAGR of 21.0% from 2022 to 2031.

Autologous cell therapy is a novel therapeutic approach that is patient-specific and involves isolating & developing cells before reinfusing them back into the same person (for CAR-T cell therapy, isolated cells are genetically modified before reintroduction). Autologous cell therapy reduces the systemic immunological reactions, bio-incompatibility, and disease transmission hazards connected to grafts or cells that were not grown from the individual. It is used for treating various cancer, musculoskeletal, dermatological, neurodegenerative, & cardiac diseases, and others disorders.□

The growth of global autologous cell therapy market is majorly driven by increase in demand for autologous cell therapy, owing to rise in R&D institutes & organizations for developing autologous cell therapy products and surge in chronic diseases especially cancer. For instance, in June 2020, FDA approved the product of Gilead Sciences Inc., Kite's Tecartus, an autologous CAR T-cell treatment for relapsed or refractory mantle cell lymphoma. In addition, rise in neurodegenerative disorders and upsurge in musculoskeletal disorders globally drive the market. Increasing emphasis on the replacement or regeneration of human cells, tissues, and organs to restore normal functionality to repair or replace cells in human tissues and organs that have undergone injury or illness and become damaged or dysfunctional further drives demand for autologous cell therapy and boosts the market growth. It can be accomplished by promoting the body's own cells to heal or by treating a patient with their own healthy cells.□ Furthermore, automation in adult stem cells and cord blood processing & storage are the key technological advancements that fuel growth of the autologous cell therapy market. However, high cost and lower treatment facilities associated with autologous cell therapy may hinder the market growth. Conversely, high growth potential in untapped economies is anticipated to provide lucrative opportunities to the market players.

The autologous cell therapy market is segmented on the basis of therapeutic area, end user, and region. By therapeutic area, the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

market is bifurcated into cancer and others. The cancer segment is further categorized into lymphoma, acute lymphocytic leukemia, and others. On the basis of end user, the market is segregated into hospitals and cancer treatment centers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).

Major key players that operate in the autologous cell therapy market are Bristol Myers Squibb, CORESTEM, Inc., GC Biopharma Corp (GC Cell), Gilead Sciences, Inc. (Kite Pharma, Inc.), Holostem Therapie Avanzate S.r.l., Johnson & Johnson Private Limited (Janssen Biotech, Inc), Novartis AG, Sanpower Group (Dendreon Pharmaceuticals LLC.), Tego Science, and Vericel Corporation.

Key Benefits For Stakeholders

-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the autologous cell therapy market analysis from 2021 to 2031 to identify the prevailing autologous cell therapy market opportunities.

-The market research is offered along with information related to key drivers, restraints, and opportunities.

-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

-In-depth analysis of the autologous cell therapy market segmentation assists to determine the prevailing market opportunities.

-Major countries in each region are mapped according to their revenue contribution to the global market.

-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

-The report includes the analysis of the regional as well as global autologous cell therapy market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Therapeutic area

- Others
- Cancer
- Type
- Lymphoma
- Acute lymphocytic leukemia
- Others

By End user

- Hospitals
- Cancer treatment centers

By Region

- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East And Africa
- Key Market Players
- Bristol Myers Squibb
- Novartis
- Vericel Corporation
- Gilead Sciences (Kite Pharma, Inc.)
- Johnson & Johnson(Janssen Biotech, Inc)
- Tego Science
- Sanpower Group (Dendreon Pharmaceuticals LLC.)
- Holostem Terapie Avanzate S.r.l.
- GC Biopharma (GC Cell)
- CORESTEM, Inc

Table of Contents:

CHAPTER 1:INTRODUCTION

- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
 - 1.4.1.Secondary research
 - 1.4.2.Primary research
 - 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

- 2.1.Key findings of the study
- 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

- 3.1.Market definition and scope
- 3.2.Key findings
 - 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
 - 3.5.1.Drivers
 - 3.5.2.Restraints
 - 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: AUTOLOGOUS CELL THERAPY MARKET, BY THERAPEUTIC AREA

- 4.1 Overview
 - 4.1.1 Market size and forecast
- 4.2 Cancer
 - 4.2.1 Key market trends, growth factors and opportunities
 - 4.2.2 Market size and forecast, by region

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2.3 Market share analysis by country
- 4.2.4 Cancer Autologous Cell Therapy Market by Type
- 4.3 Others
 - 4.3.1 Key market trends, growth factors and opportunities
 - 4.3.2 Market size and forecast, by region
 - 4.3.3 Market share analysis by country
- CHAPTER 5: AUTOLOGOUS CELL THERAPY MARKET, BY END USER
 - 5.1 Overview
 - 5.1.1 Market size and forecast
 - 5.2 Hospitals
 - 5.2.1 Key market trends, growth factors and opportunities
 - 5.2.2 Market size and forecast, by region
 - 5.2.3 Market share analysis by country
 - 5.3 Cancer treatment centers
 - 5.3.1 Key market trends, growth factors and opportunities
 - 5.3.2 Market size and forecast, by region
 - 5.3.3 Market share analysis by country
- CHAPTER 6: AUTOLOGOUS CELL THERAPY MARKET, BY REGION
 - 6.1 Overview
 - 6.1.1 Market size and forecast
 - 6.2 North America
 - 6.2.1 Key trends and opportunities
 - 6.2.2 North America Market size and forecast, by Therapeutic area
 - 6.2.3 North America Market size and forecast, by End user
 - 6.2.4 North America Market size and forecast, by country
 - 6.2.4.1 U.S.
 - 6.2.4.1.1 Key market trends, growth factors and opportunities
 - 6.2.4.1.2 Market size and forecast, by Therapeutic area
 - 6.2.4.1.3 Market size and forecast, by End user
 - 6.2.4.2 Canada
 - 6.2.4.2.1 Key market trends, growth factors and opportunities
 - 6.2.4.2.2 Market size and forecast, by Therapeutic area
 - 6.2.4.2.3 Market size and forecast, by End user
 - 6.2.4.3 Mexico
 - 6.2.4.3.1 Key market trends, growth factors and opportunities
 - 6.2.4.3.2 Market size and forecast, by Therapeutic area
 - 6.2.4.3.3 Market size and forecast, by End user
 - 6.3 Europe
 - 6.3.1 Key trends and opportunities
 - 6.3.2 Europe Market size and forecast, by Therapeutic area
 - 6.3.3 Europe Market size and forecast, by End user
 - 6.3.4 Europe Market size and forecast, by country
 - 6.3.4.1 Germany
 - 6.3.4.1.1 Key market trends, growth factors and opportunities
 - 6.3.4.1.2 Market size and forecast, by Therapeutic area
 - 6.3.4.1.3 Market size and forecast, by End user
 - 6.3.4.2 France

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.4.2.1 Key market trends, growth factors and opportunities
- 6.3.4.2.2 Market size and forecast, by Therapeutic area
- 6.3.4.2.3 Market size and forecast, by End user
- 6.3.4.3 UK
 - 6.3.4.3.1 Key market trends, growth factors and opportunities
 - 6.3.4.3.2 Market size and forecast, by Therapeutic area
 - 6.3.4.3.3 Market size and forecast, by End user
- 6.3.4.4 Italy
 - 6.3.4.4.1 Key market trends, growth factors and opportunities
 - 6.3.4.4.2 Market size and forecast, by Therapeutic area
 - 6.3.4.4.3 Market size and forecast, by End user
- 6.3.4.5 Spain
 - 6.3.4.5.1 Key market trends, growth factors and opportunities
 - 6.3.4.5.2 Market size and forecast, by Therapeutic area
 - 6.3.4.5.3 Market size and forecast, by End user
- 6.3.4.6 Rest of Europe
 - 6.3.4.6.1 Key market trends, growth factors and opportunities
 - 6.3.4.6.2 Market size and forecast, by Therapeutic area
 - 6.3.4.6.3 Market size and forecast, by End user
- 6.4 Asia-Pacific
 - 6.4.1 Key trends and opportunities
 - 6.4.2 Asia-Pacific Market size and forecast, by Therapeutic area
 - 6.4.3 Asia-Pacific Market size and forecast, by End user
 - 6.4.4 Asia-Pacific Market size and forecast, by country
 - 6.4.4.1 Japan
 - 6.4.4.1.1 Key market trends, growth factors and opportunities
 - 6.4.4.1.2 Market size and forecast, by Therapeutic area
 - 6.4.4.1.3 Market size and forecast, by End user
 - 6.4.4.2 China
 - 6.4.4.2.1 Key market trends, growth factors and opportunities
 - 6.4.4.2.2 Market size and forecast, by Therapeutic area
 - 6.4.4.2.3 Market size and forecast, by End user
 - 6.4.4.3 India
 - 6.4.4.3.1 Key market trends, growth factors and opportunities
 - 6.4.4.3.2 Market size and forecast, by Therapeutic area
 - 6.4.4.3.3 Market size and forecast, by End user
 - 6.4.4.4 Australia
 - 6.4.4.4.1 Key market trends, growth factors and opportunities
 - 6.4.4.4.2 Market size and forecast, by Therapeutic area
 - 6.4.4.4.3 Market size and forecast, by End user
 - 6.4.4.5 South Korea
 - 6.4.4.5.1 Key market trends, growth factors and opportunities
 - 6.4.4.5.2 Market size and forecast, by Therapeutic area
 - 6.4.4.5.3 Market size and forecast, by End user
 - 6.4.4.6 Rest of Asia-Pacific
 - 6.4.4.6.1 Key market trends, growth factors and opportunities
 - 6.4.4.6.2 Market size and forecast, by Therapeutic area

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.4.4.6.3 Market size and forecast, by End user
- 6.5 LAMEA
 - 6.5.1 Key trends and opportunities
 - 6.5.2 LAMEA Market size and forecast, by Therapeutic area
 - 6.5.3 LAMEA Market size and forecast, by End user
 - 6.5.4 LAMEA Market size and forecast, by country
 - 6.5.4.1 Latin America
 - 6.5.4.1.1 Key market trends, growth factors and opportunities
 - 6.5.4.1.2 Market size and forecast, by Therapeutic area
 - 6.5.4.1.3 Market size and forecast, by End user
 - 6.5.4.2 Middle East And Africa
 - 6.5.4.2.1 Key market trends, growth factors and opportunities
 - 6.5.4.2.2 Market size and forecast, by Therapeutic area
 - 6.5.4.2.3 Market size and forecast, by End user

CHAPTER 7: COMPANY LANDSCAPE

- 7.1. Introduction
- 7.2. Top winning strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

- 8.1 Bristol Myers Squibb
 - 8.1.1 Company overview
 - 8.1.2 Company snapshot
 - 8.1.3 Operating business segments
 - 8.1.4 Product portfolio
 - 8.1.5 Business performance
 - 8.1.6 Key strategic moves and developments
- 8.2 Novartis
 - 8.2.1 Company overview
 - 8.2.2 Company snapshot
 - 8.2.3 Operating business segments
 - 8.2.4 Product portfolio
 - 8.2.5 Business performance
 - 8.2.6 Key strategic moves and developments
- 8.3 Vericel Corporation
 - 8.3.1 Company overview
 - 8.3.2 Company snapshot
 - 8.3.3 Operating business segments
 - 8.3.4 Product portfolio
 - 8.3.5 Business performance
 - 8.3.6 Key strategic moves and developments
- 8.4 Gilead Sciences (Kite Pharma, Inc.)
 - 8.4.1 Company overview
 - 8.4.2 Company snapshot
 - 8.4.3 Operating business segments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.4.4 Product portfolio
- 8.4.5 Business performance
- 8.4.6 Key strategic moves and developments
- 8.5 Johnson & Johnson(Janssen Biotech, Inc)
- 8.5.1 Company overview
- 8.5.2 Company snapshot
- 8.5.3 Operating business segments
- 8.5.4 Product portfolio
- 8.5.5 Business performance
- 8.5.6 Key strategic moves and developments
- 8.6 Tego Science
- 8.6.1 Company overview
- 8.6.2 Company snapshot
- 8.6.3 Operating business segments
- 8.6.4 Product portfolio
- 8.6.5 Business performance
- 8.6.6 Key strategic moves and developments
- 8.7 Sanpower Group (Dendreon Pharmaceuticals LLC.)
- 8.7.1 Company overview
- 8.7.2 Company snapshot
- 8.7.3 Operating business segments
- 8.7.4 Product portfolio
- 8.7.5 Business performance
- 8.7.6 Key strategic moves and developments
- 8.8 Holostem Terapie Avanzate S.r.l.
- 8.8.1 Company overview
- 8.8.2 Company snapshot
- 8.8.3 Operating business segments
- 8.8.4 Product portfolio
- 8.8.5 Business performance
- 8.8.6 Key strategic moves and developments
- 8.9 GC Biopharma (GC Cell)
- 8.9.1 Company overview
- 8.9.2 Company snapshot
- 8.9.3 Operating business segments
- 8.9.4 Product portfolio
- 8.9.5 Business performance
- 8.9.6 Key strategic moves and developments
- 8.10 CORESTEM, Inc
- 8.10.1 Company overview
- 8.10.2 Company snapshot
- 8.10.3 Operating business segments
- 8.10.4 Product portfolio
- 8.10.5 Business performance
- 8.10.6 Key strategic moves and developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Autologous Cell Therapy Market By Therapeutic area (Cancer, Others), By End user (Hospitals, Cancer treatment centers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Market Report | 2022-10-01 | 188 pages | Allied Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Cloud Access License	\$3456.00
	Business User License	\$5730.00
	Enterprise License	\$9600.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Signature

An empty rectangular box with a thin black border, intended for a signature.